Georg Stingl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Georg Stingl has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Wolfgang Bauer
Department of Dermatology, Medical University of Vienna, Vienna, Austria
7 shared publications - Patrick M. Brunner
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
6 shared publications Franz Karlhofer
Abteilung für Immundermatologie und infektiöse Hautkrankheiten (DIAID), Universitätsklinik für Dermatologie, Medizinische Universität Wien
4 shared publications- Georg Stary
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria
4 shared publications - Christine Bangert
Medical University of Vienna
3 shared publications - Lars Einar French
Department of Dermatology and Allergy University Hospital, LMU Munich Munich Germany
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e208593
Paraneoplastic skin diseases
Paraneoplastic skin diseases (PSD) comprise a heterogeneous group of dermatoses associated with internal malignancies but are not caused by direct infiltration of the skin by tumor cells themselves. Instead, they reflect tumor-driven systemic effects mediated by hormones, growth factors, cytokines, antigens, or immune responses. A true paraneoplastic relationship is most likely when the dermatosis develops shortly before, concurrently with, or shortly after the diagnosis of the malignancy, and when both conditions follow a parallel clinical course. In this review, we revisit the concept of paraneoplastic dermatoses and propose a pragmatic classification into high-risk cutaneous paraneoplasias and low-to-moderate risk cutaneous paraneoplasias, rather than relying on the traditional distinction between “obligatory” and “facultative” entities. Particular emphasis is placed on high-risk disorders, including acrokeratosis paraneoplastica (Bazex syndrome), erythema gyratum repens, necrolytic migratory erythema, paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome, hypertrichosis lanuginosa acquisita, and selected acanthotic syndromes such as malignant acanthosis nigricans, tripe palms, and florid cutaneous papillomatosis. For each entity, we summarize the characteristic clinical presentation, common tumor associations, histopathologic clues, current concepts of pathogenesis, differential diagnoses, and therapeutic implications. We also briefly address selected low-to-moderate risk paraneoplastic dermatoses, including dermatomyositis as well as Sweet syndrome, pyoderma gangrenosum, and autoimmune bullous diseases. Recognition of PSD is of major clinical importance because cutaneous signs may precede the diagnosis of cancer and thus provide an opportunity for early detection of an otherwise occult malignancy. Close interdisciplinary collaboration among dermatologists, pathologists, oncologists, and other specialists is essential for accurate diagnosis, timely tumor work-up, and optimal patient management.
- 13 November 2026
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 2, e208593
Open AccessParaneoplastic skin diseases
Paraneoplastic skin diseases (PSD) comprise a heterogeneous group of dermatoses associated with internal malignancies but are not caused by direct infiltration of the skin by tumor cells themselves. Instead, they reflect tumor-driven systemic effects mediated by hormones, growth factors, cytokines, antigens, or immune responses. A true paraneoplastic relationship is most likely when the dermatosis develops shortly before, concurrently with, or shortly after the diagnosis of the malignancy, and when both conditions follow a parallel clinical course. In this review, we revisit the concept of paraneoplastic dermatoses and propose a pragmatic classification into high-risk cutaneous paraneoplasias and low-to-moderate risk cutaneous paraneoplasias, rather than relying on the traditional distinction between “obligatory” and “facultative” entities. Particular emphasis is placed on high-risk disorders, including acrokeratosis paraneoplastica (Bazex syndrome), erythema gyratum repens, necrolytic migratory erythema, paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome, hypertrichosis lanuginosa acquisita, and selected acanthotic syndromes such as malignant acanthosis nigricans, tripe palms, and florid cutaneous papillomatosis. For each entity, we summarize the characteristic clinical presentation, common tumor associations, histopathologic clues, current concepts of pathogenesis, differential diagnoses, and therapeutic implications. We also briefly address selected low-to-moderate risk paraneoplastic dermatoses, including dermatomyositis as well as Sweet syndrome, pyoderma gangrenosum, and autoimmune bullous diseases. Recognition of PSD is of major clinical importance because cutaneous signs may precede the diagnosis of cancer and thus provide an opportunity for early detection of an otherwise occult malignancy. Close interdisciplinary collaboration among dermatologists, pathologists, oncologists, and other specialists is essential for accurate diagnosis, timely tumor work-up, and optimal patient management.
- Open Access
- 10 April 2025
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 1
Eosinophils in skin disease: bystanders or pathogenic players?
Eosinophils, i.e. eosinophilic granulocytes, play a crucial role in the physiologic host defense against parasites but are also promoters of allergic tissue inflammation of the Th2 type. They are central players in the so-called eosinophilic dermatoses, such as Wells syndrome, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, eosinophilic fasciitis, and eosinophilic folliculitis among others. Eosinophils originate from the bone marrow, enter the skin under the influence of chemokines and other chemotactic factors, and are linked to a Th2 type cytokine milieu of IL-3, IL-4, IL-5, IL-13 and IL-31. We herewith describe the cardinal features as well as pathophysiological aspects of eosinophilic dermatoses. Moreover, we outline novel targeted treatments, including antibodies against key cytokines governing eosinophil differentiation, migration and function.
- 10 April 2025
- Published by Osterreichische Akademie der Wissenschaften, Verlag in SKINdeep
- Vol. 1
Open AccessEosinophils in skin disease: bystanders or pathogenic players?
Eosinophils, i.e. eosinophilic granulocytes, play a crucial role in the physiologic host defense against parasites but are also promoters of allergic tissue inflammation of the Th2 type. They are central players in the so-called eosinophilic dermatoses, such as Wells syndrome, hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, eosinophilic fasciitis, and eosinophilic folliculitis among others. Eosinophils originate from the bone marrow, enter the skin under the influence of chemokines and other chemotactic factors, and are linked to a Th2 type cytokine milieu of IL-3, IL-4, IL-5, IL-13 and IL-31. We herewith describe the cardinal features as well as pathophysiological aspects of eosinophilic dermatoses. Moreover, we outline novel targeted treatments, including antibodies against key cytokines governing eosinophil differentiation, migration and function.
- Open Access
- 5 October 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (10) , 2927-2928
Correction: Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates
- 5 October 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (10) , 2927-2928
Open AccessCorrection: Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates
- Open Access
- 22 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2299-2330
Consensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates
Atopic dermatitis often begins in infancy and follows a chronic course of exacerbations and remissions. The etiology is complex and involves numerous factors that contribute to skin barrier defect and inflammation. In the Middle East, the burden of atopic dermatitis is understudied. Epidemiological data specific to the Gulf region are scarce but reveal a prevalence of up to about 40% in the United Arab Emirates. Region-specific factors, such as the climate and the frequency of consanguineous marriages, may affect atopic dermatitis incidence, prevalence, and evolution over time. A panel of experts predominantly from the United Arab Emirates analyzed the evidence from published guidelines, and considered expert guidance and local treatment practices to develop clear recommendations for the management of atopic dermatitis in the United Arab Emirates. They encourage a systematic approach for the diagnosis and treatment, using disease severity scores and quality-of-life measurement tools. Treatment recommendations take into consideration both established therapies and the approved systemic biologics dupilumab and tralokinumab, and the Janus kinase inhibitors baricitinib, upadacitinib, and abrocitinib.
- 22 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2299-2330
Open AccessConsensus Recommendations for the Management of Atopic Dermatitis in the United Arab Emirates
Atopic dermatitis often begins in infancy and follows a chronic course of exacerbations and remissions. The etiology is complex and involves numerous factors that contribute to skin barrier defect and inflammation. In the Middle East, the burden of atopic dermatitis is understudied. Epidemiological data specific to the Gulf region are scarce but reveal a prevalence of up to about 40% in the United Arab Emirates. Region-specific factors, such as the climate and the frequency of consanguineous marriages, may affect atopic dermatitis incidence, prevalence, and evolution over time. A panel of experts predominantly from the United Arab Emirates analyzed the evidence from published guidelines, and considered expert guidance and local treatment practices to develop clear recommendations for the management of atopic dermatitis in the United Arab Emirates. They encourage a systematic approach for the diagnosis and treatment, using disease severity scores and quality-of-life measurement tools. Treatment recommendations take into consideration both established therapies and the approved systemic biologics dupilumab and tralokinumab, and the Janus kinase inhibitors baricitinib, upadacitinib, and abrocitinib.
- Open Access
- 1 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 631-644.e22
Development of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics
- 1 July 2024
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (3) , 631-644.e22
Open AccessDevelopment of a Cellular Assay as a Personalized Model for Testing Chronic Wound Therapeutics
- 31 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 1896-1905.e8
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis
- 31 March 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 1896-1905.e8
IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis
- 17 June 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (7) , 948-951
Pioneers in Dermatology and Venereology: an interview with Professor Georg Stingl
- 17 June 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (7) , 948-951
Pioneers in Dermatology and Venereology: an interview with Professor Georg Stingl
- Open Access
- 28 March 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00683
Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposure. During the placebo-controlled 12-week induction period, rates of serious adverse events per 100 patient-years were 10.8 and 9.6 (brodalumab 140 mg and 210 mg, respectively) vs 4.3 and 6.5 (ustekinumab and placebo, respectively); infections were the most frequent serious adverse event. Rates of serious adverse events during the comparator-controlled 52-week period were 14.4, 10.2 and 8.3 per 100 patient-years for brodalumab 210 mg, brodalumab 140 mg, and ustekinumab, respectively. Brodalumab was not associated with increased risks of malignancy, major adverse cardiac events, suicidal ideation and behaviour, or fatal events. Overall, brodalumab demonstrated an acceptable safety profile in short- and long-term treatment.
- 28 March 2022
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 102, adv00683
Open AccessSafety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials
Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposure. During the placebo-controlled 12-week induction period, rates of serious adverse events per 100 patient-years were 10.8 and 9.6 (brodalumab 140 mg and 210 mg, respectively) vs 4.3 and 6.5 (ustekinumab and placebo, respectively); infections were the most frequent serious adverse event. Rates of serious adverse events during the comparator-controlled 52-week period were 14.4, 10.2 and 8.3 per 100 patient-years for brodalumab 210 mg, brodalumab 140 mg, and ustekinumab, respectively. Brodalumab was not associated with increased risks of malignancy, major adverse cardiac events, suicidal ideation and behaviour, or fatal events. Overall, brodalumab demonstrated an acceptable safety profile in short- and long-term treatment.
- Open Access
- 24 November 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100072
Training Physician‒Scientists in Dermatology in Austria
- 24 November 2021
- Published by Elsevier in JID Innovations
- Vol. 2 (1) , 100072
Open AccessTraining Physician‒Scientists in Dermatology in Austria